Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough And Merck Plan Zetia/Lipitor Combination Following Patent Expiry

This article was originally published in The Pink Sheet Daily

Executive Summary

Ezetimibe/atorvastatin combination is intended as a complement to Vytorin, Schering-Plough says.

You may also be interested in...



Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)

Hassan discusses how the $14.4 billion Organon acquisition benefits the company as well as other potential M&A areas of interest for Schering-Plough.

Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)

Hassan discusses how the $14.4 billion Organon acquisition benefits the company as well as other potential M&A areas of interest for Schering-Plough.

Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts

Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel